Just the opposite, they die sooner than expected.
> -----Original Message-----
> From:	Elizabeth Childs [SMTP:echilds@linex.com]
> Sent:	Friday, June 04, 1999 10:00 AM
> To:	extropians@extropy.com
> Subject:	Re: beta carotene increases mortality
> 
> So when they say "increases mortality" they mean that the experimental
> subjects live longer?
> 
> Doug Skrecky wrote:
> > 
> > Citations: 1-2
> > <1>
> > Authors
> >   Omenn GS.
> > Institution
> >   School of Public Health & Community Medicine, University of
> Washington,
> >   Seattle 98195-7230, USA. gomenn@umich.edu
> > Title
> >   Chemoprevention of lung cancer: the rise and demise of
> >   beta-carotene. [Review] [124 refs]
> > Source
> >   Annual Review of Public Health.  19:73-99, 1998.
> > Abstract
> >   Beta-carotene and retinoids were the most
> >   promising agents against common cancers when the National Cancer
> Institute
> >   mounted a substantial program of population-based trials in the early
> 1980s.
> >   Both major lung cancer chemoprevention trials not only showed no
> benefit, but
> >   had significant increases in lung cancer incidence and in
> cardiovascular and
> >   total mortality. A new generation of laboratory research has
> >   been stimulated. Rational public health recommendations at this time
> include:
> >   1. Five-A-Day servings of fruits and vegetables, a doubling of current
> mean
> >   intake; 2. systematic investigation of the covariates of extremes of
> fruit
> >   and vegetable intake; 3. discouragement of
> >   beta-carotene supplement use, due to
> >   adverse effects in smokers and no evidence of benefit in non-smokers;
> 4.
> >   multilevel research to develop and evaluate candidate chemoprevention
> agents
> >   to prevent lung and other common cancers; and 5. continued priority
> for
> >   smoking prevention, smoking cessation, and avoidance of known
> carcinogens in
> >   the environment. [References: 124]
> > 
> > <2>
> > Authors
> >   Heinonen OP.  Albanes D.  Virtamo J.  Taylor PR.  Huttunen JK.
> Hartman AM.
> >   Haapakoski J.  Malila N.  Rautalahti M.  Ripatti S.  Maenpaa H.
> Teerenhovi
> >   L.  Koss L.  Virolainen M.  Edwards BK.
> > Institution
> >   Department of Public Health, University of Helsinki, Finland.
> > Title
> >   Prostate cancer and supplementation with alpha-tocopherol and
> >   beta-carotene: incidence and
> >   mortality in a controlled trial [see comments].
> > Comments
> >   Comment in: J Natl Cancer Inst 1998 Mar 18;90(6):414-5, Comment in: J
> Natl
> >   Cancer Inst 1998 Mar 18;90(6):416-7
> > Source
> >   Journal of the National Cancer Institute.  90(6):440-6, 1998 Mar 18.
> > Abstract
> >   BACKGROUND: Epidemiologic studies have suggested that vitamin E and
> >   beta-carotene may each influence the
> >   development of prostate cancer. In the Alpha-Tocopherol,
> >   Beta-Carotene Cancer Prevention Study, a
> >   controlled trial, we studied the effect of alpha-tocopherol (a form of
> >   vitamin E) and beta-carotene
> >   supplementation, separately or together, on prostate cancer in male
> smokers.
> >   METHODS: A total of 29133 male smokers aged 50-69 years from
> southwestern
> >   Finland were randomly assigned to receive alpha-tocopherol (50 mg),
> >   beta-carotene (20 mg), both agents, or
> >   placebo daily for 5-8 years (median, 6.1 years). The supplementation
> effects
> >   were estimated by a proportional hazards model, and two-sided P values
> were
> >   calculated. RESULTS: We found 246 new cases of and 62 deaths from
> prostate
> >   cancer during the follow-up period. A 32% decrease (95% confidence
> interval
> >   [CI] = -47% to -12%) in the incidence of prostate cancer was observed
> among
> >   the subjects receiving alpha-tocopherol (n = 14564) compared with
> those not
> >   receiving it (n = 14569). The reduction was evident in clinical
> prostate
> >   cancer but not in latent cancer. Mortality from prostate
> >   cancer was 41% lower (95% CI = -65% to -1%) among men receiving
> >   alpha-tocopherol. Among subjects receiving
> >   beta-carotene (n = 14560), prostate cancer
> >   incidence was 23% higher (95% CI = -4%-59%) and mortality
> >   was 15% higher (95% CI = -30%-89%) compared with those not receiving
> it (n =
> >   14573). Neither agent had any effect on the time interval between
> diagnosis
> >   and death. CONCLUSIONS: Long-term supplementation with
> alpha-tocopherol
> >   substantially reduced prostate cancer incidence and
> >   mortality in male smokers. Other controlled trials are
> >   required to confirm the findings.